Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Geographic Atrophy Market to Surge Significantly During the Forecast Period (2025–2034) Due to Rising Adoption of Complement Inhibitor Therapies | DelveInsight

globenewswire.com
JNJ OCGN Ocugen is mentioned for its investigational drug OCU410 for geographic atrophy, indicating its involvement in the development of new treatments for this condition. APLS Apellis Pharmaceuticals reported strong Q4 sales for SYFOVRE, indicating robust growth and market acceptance for their geographic atrophy treatment. ALXN IONS Ionis Pharmaceuticals is mentioned for its investigational drug IONIS-FB-LRx for geographic atrophy, indicating its involvement in developing new therapies. BLTE Belite Bio is developing Tinlarebant for geographic atrophy and is conducting Phase III trials, showing progress in their drug development pipeline. LCTX Lineage Cell Therapeutics (CellCure Neurosciences) is developing OpRegen for geographic atrophy, indicating ongoing research and development in this therapeutic area. REGN Regeneron Pharmaceuticals is mentioned in the context of age-related macular degeneration clinical trials, suggesting potential involvement in related eye disease research. AVNX NBIX NGM Biopharmaceuticals is mentioned for its investigational drug NGM621 for geographic atrophy, indicating its participation in the development of new treatments. STE Stealth BioTherapeutics is developing Elamipretide for geographic atrophy, indicating ongoing research and development in this therapeutic area. COG AVD Aviceda Therapeutics is developing AVD-104 for geographic atrophy, indicating its participation in the development of new treatments for this condition. OCUGEN

New York, USA, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Geographic Atrophy Market to Surge Significantly During the Forecast Period (2025–2034) Due to Rising Adoption of Complement Inhibitor Therapies | DelveInsight

The dynamics of the geographic atrophy market are expected to change in the coming years due to the rising global prevalence driven by aging populations, demand for disease-modifying interventions, and the launch of emerging therapies such as Gildeuretinol (Alkeus Pharmaceuticals), Tinlarebant (Belite Bio), AVD-104 (Aviceda Therapeutics), JNJ-1887 (Johnson & Johnson Innovative Medicine), OGX-110 (Ocugenix), OCU410 (Ocugen), BI 1584862 (Boehringer Ingelheim), and others.

DelveInsight’s Geographic Atrophy Market Insights report includes a comprehensive understanding of current treatment practices, emerging geographic atrophy drugs, market share of individual therapies, and current and forecasted geographic atrophy market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).

Geographic Atrophy Market Summary

Discover which geographic atrophy medications are expected to grab the market share @ Geographic Atrophy Market Report

Key Factors Driving the Growth of the Geographic Atrophy Market

Rising Geographic Atrophy Prevalence

The prevalence of geographic atrophy, an advanced form of age-related macular degeneration, is steadily rising due to global population ageing and increased life expectancy. As more individuals enter older age groups, the number of those at risk for geographic atrophy has grown significantly.

Emerging Diagnostic Technologies in Geographic Atrophy

New diagnostic technologies, such as spectral-domain OCT and fundus autofluorescence, have emerged, giving ophthalmologists a clearer picture of the eye and aiding the confirmation of anatomic endpoints for geographic atrophy.

ANX007 Milestone in Geographic Atrophy

ANX007 is the first therapeutic candidate for the treatment of geographic atrophy to receive PRIME designation in the EU, which provides early and proactive support to developers of promising medicines that may offer a major therapeutic advantage over existing treatments or benefit patients without treatment options.

Evidence Supporting RPE Cell Therapy for Geographic Atrophy

Data from both CPCB-RPE1 and OpRegen provide a very strong likelihood that RPE cells are an effective means of treating geographic atrophy.

Launch of Emerging Geographic Atrophy Drugs

The launch of geographic atrophy drugs such as Gildeuretinol (Alkeus Pharmaceuticals), Tinlarebant (Belite Bio), AVD-104 (Aviceda Therapeutics), JNJ-1887 (Johnson & Johnson Innovative Medicine), OGX-110 (Ocugenix), OCU410 (Ocugen), BI 1584862 (Boehringer Ingelheim), JNJ-1887 sCD59 (Janssen Research & Development, LLC), OpRegen (Lineage Cell Therapeutics (CellCure Neurosciences) and Roche), CT1812 (Cognition Therapeutics), Elamipretide (Stealth BioTherapeutics), EG-301 (Evergreen Therapeutics), ANX007 (Annexon Biosciences), NGM621 (NGM Biopharmaceuticals), Danicopan (ALXN2040) (AstraZeneca/Alexion Pharmaceuticals), IONIS-FB-LRx (Ionis Pharmaceuticals/Roche), CPCB-RPE1 (Regenerative Patch Technologies), and others are expected to change the dynamics of the geographic atrophy market in the coming years.

Geographic Atrophy Market Analysis

Agents that modulate the immune response have become the most advanced segment within clinical research for geographic atrophy, marking a major milestone as the first and only class of therapies to reach the market so far. The FDA approvals of IZERVAY (avacincaptad pegol) and SYFOVRE (pegcetacoplan) represent significant breakthroughs in this space.

While IZERVAY and SYFOVRE offer new hope for individuals with late-stage AMD, they also represent only the beginning of therapeutic progress for geographic atrophy. Safety-related setbacks temporarily slowed SYFOVRE’s early momentum and dampened its initial market lead. Nevertheless, Apellis reported strong Q4 sales, demonstrating robust growth for SYFOVRE. Looking ahead, with several new therapies expected to seek regulatory approval between 2025 and 2027, the evolution of the geographic atrophy treatment landscape will be worth watching. For now, SYFOVRE and IZERVAY face no immediate competitive threats, as no other products are nearing approval.

Surgical approaches for geographic atrophy management include the PRIMA Bionic Vision System, the SING-IMT implant, and the OcuDyne neuro-interventional procedure. A wide range of therapies is currently in development to slow disease progression and preserve macular function in dry AMD. Among the promising candidates under investigation are ALK-001, Tinlarebant, Elamipretide, and OGX-110. Many of these aim to prevent disease onset or halt worsening.

Given the older demographic affected by geographic atrophy, treatments with every-other-month dosing may see higher demand. As a result, options offering monthly dosing, or even a one-time administration, could capture meaningful market share. With a large patient population and considerable unmet need, future therapies have significant potential to become the standard of care.

Learn more about the geographic atrophy treatment options @ Geographic Atrophy Treatment Market

Geographic Atrophy Competitive Landscape

Some of the geographic atrophy drugs in clinical trials include Gildeuretinol (Alkeus Pharmaceuticals), Tinlarebant (Belite Bio), AVD-104 (Aviceda Therapeutics), JNJ-1887 (Johnson & Johnson Innovative Medicine), OGX-110 (Ocugenix), OCU410 (Ocugen), BI 1584862 (Boehringer Ingelheim), JNJ-1887 sCD59 (Janssen Research & Development, LLC), OpRegen (Lineage Cell Therapeutics (CellCure Neurosciences) and Roche), CT1812 (Cognition Therapeutics), Elamipretide (Stealth BioTherapeutics), EG-301 (Evergreen Therapeutics), ANX007 (Annexon Biosciences), NGM621 (NGM Biopharmaceuticals), Danicopan (ALXN2040) (AstraZeneca/Alexion Pharmaceuticals), IONIS-FB-LRx (Ionis Pharmaceuticals/Roche), CPCB-RPE1 (Regenerative Patch Technologies), and others.

Alkeus Pharmaceuticals’ Gildeuretinol (ALK-001) is an oral, once-daily investigational therapy for geographic atrophy. It is a chemically modified form of vitamin A designed to limit the buildup of toxic by-products that contribute to retinal degeneration. In addition to geographic atrophy, ALK-001 is also being tested for potential use in Stargardt disease.

Belite Bio’s Tinlarebant is an innovative oral drug designed to reduce harmful by-products of the visual cycle that drive STGD1 and contribute to geographic atrophy, an advanced form of dry AMD. A global, two-year Phase III trial (PHOENIX) is currently underway. This randomized, double-masked, placebo-controlled study is assessing Tinlarebant’s safety and effectiveness in patients with geographic atrophy. In November 2023, Belite Bio received MHRA approval in the UK to proceed with this Phase III study. The company plans an interim analysis at the midpoint of the trial.

Ocugenix’s OGX-110, formerly known as Ocu-110, is a small-molecule therapy that precisely targets the CXCR3 signaling pathway—an essential regulator of tissue repair that helps remove abnormal blood vessels, limit fibrosis, and restore the balance of wound healing. By binding to the natural CXCR3 receptor site, OGX-110 promotes a regenerative healing response, counteracting pro-angiogenic and pro-fibrotic factors such as VEGF. The therapy is currently in Phase I clinical testing.

The anticipated launch of these emerging geographic atrophy therapies are poised to transform the geographic atrophy market landscape in the coming years. As these cutting-edge geographic atrophy therapies continue to mature and gain regulatory approval, they are expected to reshape the geographic atrophy market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about new treatment for geographic atrophy, visit @ Geographic Atrophy Medication

Recent Developments in the Geographic Atrophy Market

What is Geographic Atrophy?

Geographic atrophy is an advanced form of age-related macular degeneration (AMD), a progressive eye disease that affects the retina, the light-sensitive tissue at the back of the eye. In geographic atrophy, areas of retinal cells, including the photoreceptors, retinal pigment epithelium (RPE), and underlying choriocapillaris, gradually degenerate, creating well-defined patches of vision loss. These areas expand over time, leading to difficulties with tasks such as reading, recognizing faces, and seeing in low light. Although geographic atrophy does not typically cause complete blindness, it can severely impair central vision and quality of life. Currently, geographic atrophy remains a chronic, irreversible condition, but emerging therapies aim to slow its progression.

Geographic Atrophy Epidemiology Segmentation

The geographic atrophy epidemiology section provides insights into the historical and current geographic atrophy patient pool and forecasted trends for the leading markets. In geographic atrophy cases, moderate-to-severe visual impairment is predominant, accounting for more than 40%, while occurrences requiring surgery or leading to legal blindness are less common.

The geographic atrophy market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets segmented into:

Download the report to understand geographic atrophy management @ Geographic Atrophy Treatment Options

Scope of the Geographic Atrophy Market Report

Discover more about geographic atrophy drugs in development @ Geographic Atrophy Clinical Trials

Table of Contents

Related Reports

Geographic Atrophy Clinical Trial Analysis

Geographic Atrophy Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key geographic atrophy companies, including Ionis Pharmaceuticals, IVERIC bio, Apellis Pharmaceuticals, Inc., NGM Biopharmaceuticals, Annexon Inc., Genentech, Alexion AstraZeneca Rare Disease, ONL Therapeutics, Alkeus Pharmaceuticals, Regenerative Patch Technologies, LLC, Astellas Pharma Inc., Gemini Therapeutics, Boehringer Ingelheim, Cell Cure Neurosciences LTD, Stealth BioTherapeutics Inc., Hemera Biosciences LLC, Gyroscope Therapeutics Limited, Eyevensys, Nanoscope Therapeutics, Inc., Catalyst Biosciences, Novartis, among others.

Age-related Macular Degeneration Market

Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key AMD companies, including Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Evergreen Therapeutics, Alkeus Pharmaceuticals, Ribomic USA Inc, Outlook Therapeutics, Inc., Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Novartis, Luxa Biotechnology, Gemini Therapeutics, among others.

Age-related Macular Degeneration Clinical Trial Analysis

Age-related Macular Degeneration Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key age-related macular degeneration companies including Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics, Inc., Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Luxa Biotechnology, Gemini Therapeutics, among others.

Dry Age-related Macular Degeneration Market

Dry Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key dry AMD companies including Alkeus Pharmaceuticals, Belite Bio, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Allegro Ophthalmics, Lineage Cell Therapeutics (CellCure Neurosciences), Roche, Cognition Therapeutics, Stealth BioTherapeutics, Annexon Biosciences, Astellas Pharma, Iveric Bio, Apellis Pharmaceuticals, among others.

Wet Age-related Macular Degeneration Market

Wet Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key wet AMD companies including EyePoint Pharmaceuticals, Inc., AbbVie, Caregen Co. Ltd., Exegenesis Bio, Shanghai Henlius Biotech, Skyline Therapeutics, 4D Molecular Therapeutics, Ocugenix Corporation, Adverum Biotechnologies, Inc., Ashvattha Therapeutics, Inc., AiViva BioPharma, Inc., Ocular Therapeutix, Inc., Clearside Biomedical, Inc., Hoffmann-La Roche, Kyowa Kirin, Inc., Opthea Limited, AffaMed Therapeutics Limited, EyeBiotech Ltd., Novartis, among others.

DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.

Other Business Pharmaceutical Consulting Services

Healthcare Conference Coverage

Pipeline Assessment

Healthcare Licensing Services

Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.